Citations 3
Nature-derived gelatin-based antifungal nanotherapeutics for combatting Candida albicans biofilms
Nabawy, Ahmed , Park, Jungmi , Nayar, Varun, Patel, Robin , Patel, Robin , Rotello, Vincent M , Makabenta, Jessa Marie , Huang, Rui , Rotello, Vincent M.
Environmental Science: Nano | November 9, 2023 | Volume: 11 | Issue: 2 | Pages: 637-644
Biodegradable and all-natural gelatin-based nanoemulsions encapsulate and stabilize antifungal essential oils to provide efficient penetration and eradication of drug-resistant fungal biofilms without resistance generation.
Nanotherapeutics using all-natural materials. Effective treatment of wound biofilm infections using crosslinked nanoemulsions
Li, Cheng-Hsuan , Landis, Ryan F., Nabawy, Ahmed , Tronchet, Tiphaine, Archambault, Danielle , Huang, Rui , Golan, Morgane, Cui, Wei , Mager, Jesse , Schmidt-Malan, Suzannah M., Patel, Robin , Patel, Robin , Makabenta, Jessa Marie , Liu, Yuanchang , Gupta, Akash , Rotello, Vincent M.
Materials Horizons | March 18, 2021 | Volume: 8 | Issue: 6 | Pages: 1776-1782
All-natural cross-linked nanoemulsions provide effective treatment of wound biofilm infections.
In situ Generation of Antibiotics using Bioorthogonal “Nanofactories”
Li, Cheng‐Hsuan , Huang, Rui , Schmidt-Malan, Suzannah M., Schmidt-Malan, Suzannah, Makabenta, Jessa Marie , Patel, Robin , Rotello, Vincent M.
Microbiology Insights | February 24, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available
Prodrug strategies use chemical modifications to improve the pharmacokinetic properties and therefore therapeutic effects of parent drugs. Traditional prodrug approaches use endogenous enzymes for activation. Bioorthogonal catalysis uses processes that endogenous enzymes cannot access, providing a complementary strategy for prodrug uncaging. Site-selective activation of prodrugs to drugs (uncaging) using synthetic catalysts is a promising strategy for localized drug activation. We discuss here recent studies that incorporate metal catalysts into polymers and nanoparticle scaffolds to provide biocompatible “enzyme-like” catalysts that can penetrate bacterial biofilms and activate prodrug antibiotics in situ, affording a new strategy to treat bacterial biofilm infections with the potential for reduced off-target effects.